SPRO Spero Therapeutics, Inc.
Nasdaq · SEC CIK 1701108 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $552.0K 6 sales by 2 insiders
- Filings on record
- 124 since 2021-08-18, latest 2026-08-06 18:49
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Rajavelu Esther | See Remarks | — | $406.8K |
| Keutzer Timothy | COO | — | $145.2K |
| Tregoning Kathleen | Dir | — | — |
| Zack Debra | Chief Medical Off | — | — |
| Smith Cynthia | Dir | — | — |
| Jackson Scott Thomas | Dir | — | — |
| VINK PATRICK V.J.J. | Dir | — | — |
| Deshpande Milind | Dir | — | — |
| Pottage John C Jr | Dir | — | — |
| THOMAS FRANK E | Dir | — | — |
Transactions 123
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-03 | 2022-02-01 | SPRO | Shukla Sath | CFO | A - Grant | $0.00 | +38.0K | 62.1K | +158% | $0 |
| D | 2022-02-03 | 2022-02-01 | SPRO | Mahadevia Ankit | CEO, Pres, Dir | A - Grant | $0.00 | +134.2K | 278.2K | +93% | $0 |
| D | 2022-02-03 | 2022-02-01 | SPRO | JOSEPH TAMARA L | CLO | A - Grant | $0.00 | +38.0K | 62.1K | +158% | $0 |
| I | 2022-02-01 | 2022-01-31 | SPRO | Aquilo Capital Management, LLC | 10% | P - Purchase | $11.59 | +125.0K | 5.15M | +2% | +$1.45M |
| I | 2022-01-26 | 2022-01-24 | SPRO | Aquilo Capital, L.P. | 10% | P - Purchase | $10.89 | +1,599 | 5.02M | +0.0% | +$17.4K |
| I | 2022-01-20 | 2022-01-18 | SPRO | Aquilo Capital Management, LLC | 10% | P - Purchase | $12.41 | +48.5K | 5.02M | +1.0% | +$601.7K |
| I | 2022-01-12 | 2022-01-10 | SPRO | Aquilo Capital Management, LLC | 10% | P - Purchase | $12.93 | +8,867 | 4.97M | +0.2% | +$114.7K |
| MI | 2022-01-03 | 2021-12-29+ | SPRO | Aquilo Capital Management, LLC | 10% | P - Purchase | $15.42 | +250.5K | 4.79M | +6% | +$3.86M |
| D | 2021-12-29 | 2021-12-27 | SPRO | Mahadevia Ankit | CEO, Pres, Dir | S - Sale+OE | $14.58 | -8,000 | 144.0K | -5% | -$116.6K |
| D | 2021-12-29 | 2021-12-27 | SPRO | Mahadevia Ankit | CEO, Pres, Dir | M - OptEx | $5.90 | +8,000 | 152.0K | +6% | +$47.2K |
| I | 2021-11-02 | 2021-10-29 | SPRO | Aquilo Capital, L.P. | 10% | P - Purchase | $17.53 | +150.0K | 4.71M | +3% | +$2.63M |
| I | 2021-10-04 | 2021-09-30 | SPRO | Aquilo Capital, L.P. | 10% | P - Purchase | $18.65 | +134.5K | 4.56M | +3% | +$2.51M |
| MI | 2021-09-15 | 2021-09-13+ | SPRO | Aquilo Capital, L.P. | 10% | P - Purchase | $18.56 | +46.4K | 4.43M | +1% | +$860.4K |
| I | 2021-09-10 | 2021-09-09 | SPRO | Aquilo Capital Management, LLC | 10% | P - Purchase | $18.50 | +24.7K | 4.38M | +0.6% | +$457.9K |
| MI | 2021-09-01 | 2021-08-30+ | SPRO | Aquilo Capital Management, LLC | 10% | P - Purchase | $18.43 | +92.7K | 4.36M | +2% | +$1.71M |
| 2021-08-30 | 2021-08-26 | SPRO | Melnick David A. | Chief Medical Off | A - Grant | $0.00 | +24.1K | 24.1K | New | $0 | |
| 2021-08-30 | 2021-08-26 | SPRO | Keutzer Timothy | Chief Development Off | A - Grant | $0.00 | +24.1K | 26.6K | +963% | $0 | |
| 2021-08-30 | 2021-08-26 | SPRO | Larkin Cristina | COO | A - Grant | $0.00 | +24.1K | 25.6K | +1,604% | $0 | |
| 2021-08-30 | 2021-08-26 | SPRO | Shukla Sath | CFO | A - Grant | $0.00 | +24.1K | 24.1K | New | $0 | |
| 2021-08-30 | 2021-08-26 | SPRO | Mahadevia Ankit | CEO, Pres, Dir | A - Grant | $0.00 | +78.2K | 144.0K | +119% | $0 | |
| 2021-08-30 | 2021-08-26 | SPRO | JOSEPH TAMARA L | CLO | A - Grant | $0.00 | +24.1K | 24.1K | New | $0 | |
| MI | 2021-08-27 | 2021-08-26+ | SPRO | Aquilo Capital, L.P. | 10% | P - Purchase | $16.67 | +36.9K | 4.25M | +0.9% | +$615.9K |
| MI | 2021-08-24 | 2021-08-20+ | SPRO | Aquilo Capital, L.P. | 10% | P - Purchase | $15.51 | +399.2K | 4.19M | +11% | +$6.19M |
Purchase Sale Sale after option exercise All abbreviations